1. A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY. (June 2017) Authors: Le Gouill, S.; Wermke, M.; Morschhauser, F.; Lim, S.T.; Salles, G.; Kloos, I.; de Burgat, V.; Becquart, M.; Paux, G.; Kraus‐Berthier, L.; Pennaforte, S.; Stilgenbauer, S.; Walewski, J.; Ribrag, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AUTOLOGOUS STEM CELL TRANSPLANT WITH HIGH DOSE MELPHALAN PREPARATIVE REGIMEN IS SAFE AND EFFECTIVE FOR ELDERLY MULTIPLE MYELOMA PATIENTS IN THE ERA OF TRIPLE INDUCTION THERAPY. (12th June 2019) Authors: Czyz, A.; Romejko‐Jarosinska, J.; Szeremet, A.; Bogucka‐Fedorczuk, A.; Majcherek, M.; Szymanski, M.; Walewski, J.; Wrobel, T. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 549 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. (June 2017) Authors: Zinzani, P.; Thieblemont, C.; Melnichenko, V.; Osmanov, D.; Bouabdallah, K.; Walewski, J.; Majlis, A.; Fogliatto, L.; Caballero Barrigón, M.D.; Christian, B.; Gulbas, Z.; Özcan, M.; Salles, G.A.; Shipp, M.A.; Balakumaran, A.; Chlosta, S.; Chatterjee, A.; Armand, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MCL‐R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R‐CHOP / R‐HAD) AND a RITUXIMAB‐LENALIDOMIDE MAINTENANCE. (June 2017) Authors: Ribrag, V.; Feugier, P.; Doorduijn, J.; Delfau‐Larue, M.; Hermine, O.; Kluin‐Nelemans, H.; Dasilva, M.; Lopez‐Hernandez, A.; Walewski, J.; Szymczyk, M.; Pott, C.; Homburg, C.; Van der Velden, V.; Gameiro, P.; Garcia‐Sanz, R.; Ladetto, M.; van Krieken, H.; Cabeçadas, J.; Rymkiewicz, G.; Klapper, W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MOLECULAR ANALYSES AND AN INNOVATIVE DIAGNOSTIC ALGORITHM IN MYC‐NEGATIVE BURKITT‐LIKE LYMPHOMA WITH 11Q ABERRATION: A SINGLE INSTITUTION EXPERIENCE. (12th June 2019) Authors: Rymkiewicz, G.; Zajdel, M.; Paziewska, A.; Blachnio, K.; Grygalewicz, B.; Woroniecka, R.; Dabrowska, M.; Bystydzienski, Z.; Romejko‐Jarosinska, J.; Kulecka, M.; Kulinczak, M.; Sromek, M.; Rygier, J.; Borysiuk, A.; Pienkowska‐Grela, B.; Czyz‐Domanska, K.; Miloszewska, J.; Szafron, L.; Prochorec‐So... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8). (12th June 2019) Authors: Paszkiewicz‐Kozik, E.; Michalski, W.; Taszner, M.; Knopińska‐Posłuszny, W.; Mordak‐Domagała, M.; Najda, J.; Borawska, A.; Romejko‐Jarosińska, J.; Chełstowska, M.; Świerkowska, M.; Dąbrowska‐Iwanicka, A.; Malenda, A.; Druzd‐Sitek, A.; Konecki, R.; Kuniega, B.; Osowiecki, M.; Ostrowska, B.; Szpila,... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OUTCOME OF PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA WHO FAILED TO PROCEED TO OR RELAPSED AFTER HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. (12th June 2019) Authors: Romejko‐Jarosinska, J.; Paszkiewicz‐Kozik, E.; Popławska, L.; Targonski, L.; Szymanski, M.; Walewski, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation. (June 2017) Authors: Zaucha, J.M.; Khair, W.; Biecek, P.; Subocz, E.; Tajer, J.; Kulikowski, W.; Panebianco, M.; Grad, J.; Rybka, J.; Kroll‐Balcerzak, R.; Romanowicz, A.; Chmielowska, E.; Kurczab, P.; Malkowski, B.; Juszczynski, P.; Cimino, G.; Walewski, J.; El‐Galaly, T.C.; Gallamini, A.; Dann, E.J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PRIMARY BREAST DIFFUSE LARGE B‐CELL LYMPHOMA. CLINICAL FEATURES AND OUTCOME IN 55 PATIENTS. POLISH LYMPHOMA RESEARCH GROUP STUDY. (12th June 2019) Authors: Romejko‐Jarosinska, J.; Paszkiewicz‐Kozik, E.; Sokołowska‐Drozd, J.; Waszczuk‐Gajda, A.; Kotarska, M.; Blamek, S.; Kulma‐Kreft, M.; Kurczab, P.; Kumiega, B.; Sawczuk, W.; Zaucha, J.; Walewski, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. (June 2017) Authors: Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y.H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; Sanches, J.; Ortiz‐Romero, P.; Akilov, O.; Trotman, J.; Taylor, K.; Dalle, S.; Weichenthal, M.; Walewski, J.; Fisher, D.; Wang, Y. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗